Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) CEO Robert Barrow sold 15,659 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $7.22, for a total value of $113,057.98. Following the transaction, the chief executive officer now directly owns 564,543 shares in the company, valued at approximately $4,076,000.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Mind Medicine (MindMed) Price Performance
Mind Medicine (MindMed) stock opened at $7.27 on Thursday. The company’s 50 day simple moving average is $8.36 and its 200-day simple moving average is $6.82. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.91 and a quick ratio of 3.91. Mind Medicine has a 1 year low of $2.41 and a 1 year high of $12.22.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.06. Equities research analysts forecast that Mind Medicine will post -1.36 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Report on MNMD
Institutional Investors Weigh In On Mind Medicine (MindMed)
Institutional investors and hedge funds have recently modified their holdings of the company. SageView Advisory Group LLC purchased a new position in Mind Medicine (MindMed) during the 1st quarter valued at about $25,000. Bailard Inc. acquired a new stake in shares of Mind Medicine (MindMed) during the fourth quarter worth about $63,000. Mitchell Mcleod Pugh & Williams Inc. purchased a new position in shares of Mind Medicine (MindMed) in the fourth quarter valued at approximately $73,000. Jump Financial LLC grew its holdings in shares of Mind Medicine (MindMed) by 8.3% in the fourth quarter. Jump Financial LLC now owns 36,826 shares of the company’s stock valued at $135,000 after purchasing an additional 2,826 shares in the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in Mind Medicine (MindMed) during the 1st quarter worth approximately $168,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Stories
- Five stocks we like better than Mind Medicine (MindMed)
- How to Evaluate a Stock Before BuyingÂ
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Most active stocks: Dollar volume vs share volume
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Transportation Stocks Investing
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.